Your browser doesn't support javascript.
loading
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Chan, Kam Wa; Smeijer, J David; Schechter, Meir; Jongs, Niels; Vart, Priya; Kohan, Donald E; Gansevoort, Ron T; Liew, Adrian; Tang, Sydney C W; Wanner, Christoph; de Zeeuw, Dick; Heerspink, Hiddo J L.
Afiliación
  • Chan KW; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Division of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong SAR; School of Chinese Medicine, Hong Kong Baptist University, Hong Kong
  • Smeijer JD; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Schechter M; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Jerusalem, Israel; Faculty of Medicine, Hebrew University of Jerusalem, Jeru
  • Jongs N; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Vart P; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Kohan DE; Division of Nephrology, University of Utah Health, Salt Lake City, Utah, USA.
  • Gansevoort RT; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Liew A; Mount Elizabeth Novena Hospital, Singapore.
  • Tang SCW; Division of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong SAR.
  • Wanner C; Department of Medicine, Division of Nephrology, Würzburg University Clinic, Würzburg, Germany; Department of Clinical Research and Epidemiology, Renal Research Unit, Comprehensive Heart Failure Center, Würzburg University, Würzburg, Germany.
  • de Zeeuw D; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands; The George Institute for Global Health, Sydney, New South Wales, Australia. Electronic address: h.j.lambers.heerspink@umcg.nl.
Kidney Int ; 104(6): 1219-1226, 2023 12.
Article en En | MEDLINE | ID: mdl-37657768
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Insuficiencia Renal Crónica Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 2 / Insuficiencia Renal Crónica Tipo de estudio: Clinical_trials / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article